Department of Anaesthesiology and Intensive Care, Charité - Universitaetsmedizin Berlin, Campus Charité Mitte and Campus Virchow-Klinikum, Berlin, Germany.
Institute for Clinical Pharmacology, Otto-von-Guericke-Universität, Magdeburg, Germany.
J Infect Public Health. 2015 Jul-Aug;8(4):355-63. doi: 10.1016/j.jiph.2015.01.011. Epub 2015 Mar 17.
Different dosing regimens for vancomycin are in clinical use: intermittent infusion and continuous administration. The intention of using these different dosing regimens is to reduce toxicity, to achieve target levels faster and to avoid treatment failure. The aim of this phase IV study was to compare safety and effectiveness in both administration regimens. The study was conducted in 2010 and 2011 in three postoperative intensive care units (ICUs) in a tertiary care university hospital in Berlin, Germany. Adult patients with vancomycin therapy and therapeutic drug monitoring were included. Out of 675 patients screened, 125 received vancomycin therapy, 39% with intermittent and 61% with continuous administration. Patients with continuous administration achieved target serum levels significantly earlier (median day 3 versus 4, p=0.022) and showed fewer sub-therapeutic serum levels (41% versus 11%, p<0.001). ICU mortality rate, duration of ICU stay and duration of ventilation did not differ between groups. Acute renal failure during the ICU stay occurred in 35% of patients with intermittent infusion versus 26% of patients with continuous application (p=0.324). In conclusion, continuous administration of vancomycin allowed more rapid achievement of targeted drug levels with fewer sub-therapeutic vancomycin levels observed. This might indicate that patients with more severe infections or higher variability in renal function could benefit from this form of administration.
万古霉素有不同的给药方案,包括间歇性输注和连续给药。采用这些不同的给药方案旨在降低毒性,更快地达到目标水平,并避免治疗失败。本 IV 期研究的目的是比较两种给药方案的安全性和有效性。该研究于 2010 年至 2011 年在德国柏林的一家三级教学医院的三个术后重症监护病房(ICU)进行。纳入接受万古霉素治疗和治疗药物监测的成年患者。在筛选的 675 名患者中,有 125 名接受了万古霉素治疗,其中 39%采用间歇性给药,61%采用连续给药。连续给药的患者更早达到目标血清水平(中位数第 3 天 vs. 第 4 天,p=0.022),且较少出现低于治疗范围的血清水平(41% vs. 11%,p<0.001)。两组 ICU 死亡率、ICU 住院时间和通气时间无差异。间歇性输注组有 35%的患者在 ICU 期间发生急性肾功能衰竭,而连续应用组有 26%的患者发生急性肾功能衰竭(p=0.324)。总之,万古霉素连续给药可更快地达到目标药物水平,且观察到的低于治疗范围的万古霉素水平更少。这可能表明,感染更严重或肾功能变异性更高的患者可能受益于这种给药方式。